Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · IEX Real-Time Price · USD
1.430
-0.100 (-6.54%)
At close: Jul 19, 2024, 4:00 PM
1.440
+0.010 (0.70%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 89 |
CEO | David J. Lennon Ph.D. |
Contact Details
Address: 17383 Sunset Avenue, Suite A250 Pacific Palisades, California 90272 United States | |
Phone | 424-473-8055 |
Website | aadibio.com |
Stock Details
Ticker Symbol | AADI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001422142 |
CUSIP Number | 00032Q104 |
ISIN Number | US00032Q1040 |
Employer ID | 61-1547850 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
Dr. Neil P. Desai Ph.D. | Founder, Secretary and Executive Chairman |
Dr. Loretta M. Itri F.A.C.P., M.D. | Chief Medical Officer |
Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
Raymond G. Steitz | Senior Vice President of Human Resources and Chief Human Resources Officer |
Bryan Ball | Chief Quality Officer and Senior Vice President of Manufacturing Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 12, 2024 | 8-K | Current Report |
Jun 3, 2024 | 144 | Filing |
May 8, 2024 | 10-Q | Quarterly Report |
May 8, 2024 | 8-K | Current Report |
May 3, 2024 | 424B5 | Filing |
Apr 30, 2024 | EFFECT | Notice of Effectiveness |
Apr 26, 2024 | ARS | Filing |
Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
Apr 4, 2024 | 8-K | Current Report |